SuperworthIncyte market cap INCY
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Oct 23, 2026
- $23.5B
- Highest close in our data
- $28.4B
- Sep 2017
Incyte is worth $23.5B at the close on Oct 23, 2026, at $115.71 a share.
That is up 32% over the last year and up 59% over five years.
Its highest close in our data was $28.4B in Sep 2017.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $23.5B | $18B | $25.9B | +19% |
| 2025 | $19.7B | $11B | $20.8B | +47% |
| 2024 | $13.3B | $11.6B | $16.1B | −5% |
| 2023 | $14.1B | $11.8B | $19.1B | −21% |
| 2022 | $17.9B | $14.8B | $18.5B | +10% |
| 2021 | $16.2B | $14.2B | $21.4B | −15% |
| 2020 | $19B | $14.5B | $23.1B | +0% |
| 2019 | $19B | $15.4B | $20.4B | +44% |
| 2018 | $13.3B | $12.5B | $21.1B | −34% |
| 2017 | $20B | $20B | $28.4B | +6% |
| 2016 | $18.9B | $12.2B | $20.3B | −6% |
| 2015 | $20.2B | $12.2B | $23.6B | +62% |
| 2014 | $12.5B | $7.4B | $13B | +56% |
| 2013 | $8B | $2.3B | $8.3B | +280% |
| 2012 | $2.1B | $2.1B | $3.3B | +11% |
| 2011 | $1.9B | $1.5B | $2.5B | n/a |
Against its peers
Companies in Biotechnology nearest Incyte's size, closest first, today.
| Company | Market cap |
|---|---|
| INCYIncyte | $23.5B |
| UTHRUnited Therapeutics | $25.2B |
| ALNYAlnylam Pharmaceuticals | $30B |
| EXELExelixis | $16B |
| NBIXNeurocrine Biosciences | $14.5B |
| HALOHalozyme Therapeutics | $14.3B |
| ONCBeOne Medicines | $42.9B |
| TECHBIO-TECHNE | $11.4B |
| RGENRepligen | $10B |
| KRYSKrystal Biotech | $9.2B |
| REGNRegeneron Pharmaceuticals | $82.9B |
| Peer median | $15.2B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Incyte
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.